German-headquartred Bayer Schering Pharma has launched the first ever UK TV advertisement campaign for emergency contraceptive pill, Levonelle (levonorgestrel) One Step. Whilst previous campaigns for the product have been broadcast on radio, this is the first time advertising for the brand has run on UK television.
By entering the realm of TV advertising, Bayer Schering Pharma aims to raise awareness that Levonelle One Step can be obtained over-the-counter at pharmacies as well as from general practitioners and family planning clinics. It also hopes to dispel the "morning after" myth surrounding the emergency contraceptive pill because the drug is effective for up to 72 hours after unprotected sex; however women are encouraged to take it as soon as possible after a contraception mishap has occurred because Levonelle is more effective the sooner it is taken.
The advertisement is animated in style and begins with a woman waking up next to her partner after experiencing a contraception mishap the night before. She then takes a journey to a pharmacy to request Levonelle One Step from a Pharmacist, who is trained to offer the emergency contraceptive pill appropriately, discreetly and sensitively, the company explains.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze